Synchron, a California-based company that develops neurostimulation devices for treating neurological disorders, has announced that it has raised $40 million in a Series B funding round led by Khosla Ventures. Other investors that participated in the round included General Catalyst, Mayo Clinic, and Morningside Ventures. synchron 40m series khosla.
Synchron’s flagship product is the Stentrode, a minimally invasive implantable device that enables patients with paralysis to control computer cursors, robotic limbs, and other assistive devices using their thoughts. The Stentrode is implanted into a blood vessel in the brain, where it can detect and decode neural signals and transmit them to external devices. synchron series khosla venturesparkfiercebiotech.
The Stentrode has the potential to revolutionize the treatment of neurological disorders, particularly those that result in paralysis or other forms of physical disability. The device has already shown promising results in clinical trials, with patients with paralysis able to control a computer cursor with an accuracy of over 90%. synchron 40m khosla.
The $40 million Series B funding round will be used to further develop the Stentrode and bring it to market. The company also plans to use the funds to expand its clinical trials and explore new applications of its technology. synchron series venturesparkfiercebiotech.
Synchron’s founder and CEO, Thomas Oxley, said in a statement announcing the funding round, “We’re thrilled to have the support of such a distinguished group of investors as we work to bring the Stentrode to market and help millions of people with neurological disorders live more independent and fulfilling lives. This funding will enable us to accelerate our development efforts and bring this innovative technology to the people who need it most.” synchron 40m khosla venturesparkfiercebiotech.
Khosla Ventures, which led the funding round, is a prominent venture capital firm that has invested in a number of successful startups, including Square, DoorDash, and Impossible Foods. The firm’s investment in Synchron is a testament to the potential of the Stentrode and the promise of neurostimulation technology in general. 40m series khosla.
In a statement, Vinod Khosla, founder of Khosla Ventures, said, “We believe that neurostimulation has the potential to revolutionize the treatment of neurological disorders and improve the lives of millions of people. Synchron’s innovative approach and groundbreaking technology have the potential to make a significant impact in this field, and we’re excited to support them in their mission.” synchron khosla venturesparkfiercebiotech.
Overall, Synchron’s successful Series B funding round is a positive sign for the future of neurostimulation technology and the treatment of neurological disorders. The Stentrode has the potential to transform the lives of millions of people with paralysis and other forms of physical disability, and the company’s innovative approach and focus on patient outcomes have the potential to make a significant impact in this field.